CD274 and triple-negative breast carcinoma: Atezolizumab (MPDL3280A) inhibits the PD-L1/PD-1 pathway by binding to PD-L1 and has been approved for the treatment of advanced NSCLC, triple-negative breast cancer and urothelial carcinoma 15, 71.